Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948875 | 0.91 | CTSK (0.37) | CTSKCYP3A4 | |
| SCHEMBL15948786 | 0.91 | CTSK (0.37) | CTSKCYP3A4DAGLAHTTSMN1; SMN2 | |
| SCHEMBL17174995 | 0.85 | CNR1 (0.36) | CTSKCYP3A4DAGLACNR1 | |
| SCHEMBL17174997 | 0.75 | DAGLA (0.37) | CYP3A4DAGLACNR1 | |
| SCHEMBL17972404 | 0.75 | PLA2G2A (0.44) | SMN1; SMN2 | |
| SCHEMBL15685423 | 0.74 | EPHX1 (0.32) | CTSKDAGLACNR1 | |
| SCHEMBL20830134 | 0.74 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL17972403 | 0.73 | PLA2G2A (0.45) | DAGLACNR1 | |
| SCHEMBL20830130 | 0.73 | PPARA (0.37) | CTSKCYP3A4 | |
| SCHEMBL17972405 | 0.72 | PRSS1 (0.39) | CTSKPRSS1CTSGCTRB1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | CTSK 3165/4885CYP3A4 4033/4885DAGLA 2952/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | CTSK 4104/4885CYP3A4 2123/4885DAGLA 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.